Drilling for energy in mitochondrial disease

Archives of Neurology

Volumn 66, Issue 8, 2009, Pages 931-932

  Haller, Ronald G ^a   Vissing, John ^b  

^a PRESBYTERIAN HOSPITAL OF DALLAS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BEZAFIBRATE; DICHLOROACETIC ACID; MENADIONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; RIBOFLAVIN; SUCCINIC ACID; UBIDECARENONE;

AEROBIC EXERCISE; CELL ENERGY; CELL FUNCTION; CELL VIABILITY; COMPLEX III DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; EDITORIAL; GENE MUTATION; GENE THERAPY; GLYCOLYSIS; HUMAN; LACTIC ACIDOSIS; LEIGH DISEASE; MITOCHONDRIAL RESPIRATION; NARP SYNDROME; OXIDATIVE PHOSPHORYLATION; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; UNSPECIFIED SIDE EFFECT;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOPTOSIS; ASPARTIC ACID; CELL SURVIVAL; CELLS, CULTURED; DNA MUTATIONAL ANALYSIS; DNA, MITOCHONDRIAL; ENERGY METABOLISM; GENE THERAPY; GLYCOLYSIS; HUMANS; KETOGLUTARIC ACIDS; MITOCHONDRIAL DISEASES; OXIDATIVE PHOSPHORYLATION;

EID: 68549130877     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2009.155     Document Type: Editorial

References (16)

1. DiMauro S, Schon EA. Mitochondrial disorders in the nervous system. Annu Rev Neurosci. 2008;31:91-123.
2. Mattson MP, Gleichmann M, Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron. 2008;60(5):748-766.
3. Koene S, Smeitink J. Mitochondrial medicine: entering the era of treatment. J Intern Med. 2009;265(2):193-209.
4. DiMauro S, Mancuso M. Mitochondrial diseases: therapeutic approaches. Biosci Rep. 2007;27(1-3):125-137.
5. James AM, Cocheme HM, Smith RA, Murphy MP. Interactions of mitochondriatargeted and untargeted ubiquinones with the mitochondrial respiratory chain and reactive oxygen species: implications for the use of exogenous ubiquinones as therapies and experimental tools. J Biol Chem. 2005;280(22):21295-21312.
6. Eleff S, Kennaway NG, Buist NR, et al. 31P NMR study of improvement in oxidative phosphorylation by vitamins K3 and C in a patient with a defect in electron transport at complex III in skeletal muscle. Proc Natl Acad Sci U S A. 1984; 81(11):3529-3533.
7. Tarnopolsky MA. The mitochondrial cocktail: rationale for combined nutraceutical therapy in mitochondrial cytopathies. Adv Drug Deliv Rev. 2008;60(13-14): 1561-1567.
8. Taivassalo T, Gardner JL, Taylor RW, et al. Endurance training and detraining in mitochondrial myopathies due to single large-scale mtDNA deletions. Brain. 2006; 129(Pt 12):3391-3401.
9. Jeppesen TD, Schwartz M, Olsen DB, et al. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 2006;129 (pt 12):3402-3412.
10. Narkar VA, Downes M, Yu RT, et al. AMPK and PPARδ agonists are exercise mimetics. Cell. 2008;134(3):405-415.
11. Wenz T, Diaz F, Spiegelman BM, Moraes CT. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008;8(3):249-256.
12. Bonnefont JP, Bastin J, Behin A, Djouadi F. Bezafibrate for an inborn mitochondrial beta-oxidation defect. N Engl J Med. 2009;360(8):838-840.
13. Vissing J, Gansted U, Quistorff B. Exercise intolerance in mitochondrial myopathy is not related to lactic acidosis. Ann Neurol. 2001;49(5):672-676.
14. Kaufmann P, Engelstad K, Wei Y, et al. Dichloroacetate causes toxic neuropathy in MELAS: a randomized, controlled clinical trial. Neurology. 2006;66(3):324-330.
15. Sgarbi G, Casalena GA, Baracca A, Lenaz G, DiMauro S, Solaini G. Human NARP mitochondrial mutation metabolism corrected with α-ketoglutarate/ aspartate: a potential new therapy. Arch Neurol. 2009;66(8):951-957.
16. Lambeth DO, Tews KN, Adkins S, Frohlich D, Milavetz BI. Expression of two succinyl-CoA synthetases with different nucleotide specificities in mammalian tissues.JBiol Chem. 2004;279(35):36621-36624.